Sildenafil therapy for neonatal and childhood pulmonary hypertensive vascular disease
Authors:
- Janette T. ReyesJRJanette T. Reyes
- Simon EricksonSESimon Erickson
- Ruth ArmanoRARuth Armano
- Helen HoltbyHHHelen Holtby
- Ian AdatiaIAIan Adatia
- 8 December 2010
- journal article
- research article
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 21 (2) , 187-193
Abstract
Objectives: We hypothesised that sildenafil would improve hemodynamics in children with pulmonary hypertension and attenuate rebound pulmonary hypertension after inhaled nitric oxide withdrawal.Patients and methods: We undertook an open-label, single-drug study of sildenafil in patients under 5 years of age with either symptomatic or rebound pulmonary hypertension following inhaled nitric oxide withdrawal.Results: We recruited 25 patients (median age 180 days, 10–1790) to receive sildenafil. The median right ventricular to systemic systolic blood pressure ratio before sildenafil therapy was 1.0 (0.5–1.4) and decreased to 0.5 (with a range from 0.3 to 1.3; p = 0.0002). In five patients the baseline pulmonary vascular resistance index was 10 (7.1–13.6) Wood units metre square and decreased to 5.8 (2.7–15.6) Wood units metre square (p = 0.04) at 6 months. Ten patients were treated with sildenafil for a median of 34 days (9–499) until resolution of pulmonary artery hypertension and continue to do well. Six patients continued sildenafil therapy for a median of 1002 days (384–1574) with improvement but without resolution of pulmonary hypertension. There was no change in serum creatinine, urea, liver function tests, or platelet count. In 15 patients sildenafil abolished rebound pulmonary artery hypertension following withdrawal of inhaled nitric oxide. Median right ventricular pressure to systemic systolic pressure ratio decreased from 1.0 (0.8–1.4) during nitric oxide withdrawal to 0.4 (0.3–0.8) p = 0.006 after pre-treatment with sildenafil.Conclusion: In children under 5 years of age with severe pulmonary hypertension, sildenafil therapy resulted in prolonged hemodynamic improvements without adverse effects. Sildenafil attenuated rebound pulmonary hypertension after withdrawal of inhaled nitric oxide.Keywords
This publication has 19 references indexed in Scilit:
- Stress Doppler Echocardiography in Relatives of Patients With Idiopathic and Familial Pulmonary Arterial HypertensionCirculation, 2009
- Retinal Effects of 6 Months of Daily Use of Tadalafil or SildenafilArchives of Ophthalmology (1950), 2009
- Pulmonary Artery Hypertension in Formerly Premature Infants With Bronchopulmonary Dysplasia: Clinical Features and Outcomes in the Surfactant EraPediatrics, 2007
- Cardiovascular Effects of Sildenafil in Neonates and Infants with Congenital Diaphragmatic Hernia and Pulmonary HypertensionNeonatology, 2006
- Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertensionJACC, 2004
- Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgeryIntensive Care Medicine, 2003
- Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial HypertensionCirculation, 2003
- Intravenous Sildenafil Is a Potent Pulmonary Vasodilator in Children With Congenital Heart DiseaseCirculation, 2003
- Recent advances in pulmonary vascular diseaseCurrent Opinion in Pediatrics, 2002
- Rebound Pulmonary Hypertension After Inhalation of Nitric OxideThe Annals of Thoracic Surgery, 1996